Kolf Meghan J, McPherson Christopher C, Kniska Kara S, Luecke Caitlyn M, Lahart Michael A, Pineda Jose A
J Pediatr Pharmacol Ther. 2020;25(3):241-245. doi: 10.5863/1551-6776-25.3.241.
Although levetiracetam is used for the prevention of early Post-traumatic seizures (EPTS) after traumatic brain injury (TBI), limited data exist describing the incidence of seizures in pediatric patients receiving levetiracetam prophylaxis. The objective of this research is to evaluate the prevalence of EPTS in children given prophylactic levetiracetam after severe TBI.
This study was conducted at a Level 1 pediatric trauma center and included pediatric patients with severe TBI who received levetiracetam for EPTS prophylaxis. Demographics and clinical information were retrospectively collected and evaluated. The primary outcome was prevalence of clinical or electrographic seizures within 7 days of initial injury as noted in the EMR.
In 4 of 44 patients (9%), seizures developed despite levetiracetam prophylaxis. Concurrent use of other medications with antiepileptic properties was common (91%). There were no differences in demographic or baseline clinical characteristics between the group of patients experiencing seizures and those who did not. However, craniotomy was significantly more common in the seizure group (75% vs. 18%, p = 0.03).
Children receiving prophylaxis with levetiracetam after severe TBI had a lower incidence of seizures (9%) than had previously been reported in the literature (18%). Given the limited literature available supporting the use of levetiracetam for the prevention of EPTS in children experiencing severe TBI, further study is needed to support routine use.
虽然左乙拉西坦用于预防创伤性脑损伤(TBI)后的早期创伤后癫痫发作(EPTS),但关于接受左乙拉西坦预防的儿科患者癫痫发作发生率的数据有限。本研究的目的是评估重度TBI后接受左乙拉西坦预防性治疗的儿童中EPTS的患病率。
本研究在一家一级儿科创伤中心进行,纳入了因EPTS预防而接受左乙拉西坦治疗的重度TBI儿科患者。回顾性收集并评估人口统计学和临床信息。主要结局是电子病历中记录的初始损伤后7天内临床或脑电图癫痫发作的患病率。
44例患者中有4例(9%)尽管接受了左乙拉西坦预防仍发生了癫痫发作。同时使用其他具有抗癫痫特性的药物很常见(91%)。癫痫发作组和未发作组在人口统计学或基线临床特征方面没有差异。然而,开颅手术在癫痫发作组中明显更常见(75%对18%,p = 0.03)。
重度TBI后接受左乙拉西坦预防性治疗的儿童癫痫发作发生率(9%)低于先前文献报道(18%)。鉴于支持左乙拉西坦用于预防重度TBI儿童EPTS的现有文献有限,需要进一步研究以支持常规使用。